Antiplatelet Resumption after Antiplatelet-related Intracerebral Hemorrhage: A Retrospective Hospital-based Study

Highlights • After antiplatelet-related ICH, ischemic events were more common than recurrent ICHs. • The risk of recurrent ICH with antiplatelet resumption may be overemphasized. • BP control and CAA contributed to a more robust risk for ICH recurrence. • Antiplatelet should be resumed in patients w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	World neurosurgery 2017-10, Vol.106, p.85-91
Hauptverfasser:	Teo, Kay-Cheong, FHKCP, Lau, Gary KK., FHKCP, Mak, Ryan HY, Leung, Ho-Yan, Chang, Richard SK., FHKCP, Tse, Man-Yu, FHKCP, Lee, Raymand, FHKAM, Leung, Gilberto KK., FRCSEd, MS, Siu, David CW., MD, FRCP, Cheung, Raymond TF., PhD, FRCP, Ho, Shu-Leong, MD, FRCP, Chan, Koon-Ho, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antiplatelet medication Cerebral Hemorrhage - chemically induced Cerebral Hemorrhage - mortality Drug Substitution Female Humans Intracerebral hemorrhage Ischemia - etiology Ischemia - mortality Male Neurosurgery Platelet Aggregation Inhibitors - adverse effects Recurrence Retrospective Studies Risk Factors Survivors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • After antiplatelet-related ICH, ischemic events were more common than recurrent ICHs. • The risk of recurrent ICH with antiplatelet resumption may be overemphasized. • BP control and CAA contributed to a more robust risk for ICH recurrence. • Antiplatelet should be resumed in patients with low risk of recurrent ICH.
ISSN:	1878-8750 1878-8769
DOI:	10.1016/j.wneu.2017.06.015